{"DataElement":{"publicId":"6384255","version":"1","preferredName":"Myeloproliferative Neoplasm Blast Count Less Than Or Equal To Twenty Assessment Code","preferredDefinition":"A code that represents the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages the number of blast cells blasts as a percentage of less than or equal to than 20 present in a blood sample.","longName":"MNP_BLT_LES_THN_CD","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"6384215","version":"1","preferredName":"Myeloproliferative Neoplasm Blast Count Assessment","preferredDefinition":"A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008)_The determination of the number of blast cells present in a blood sample._The final result of a determination of the value, significance, or extent of.","longName":"2674375v1.0:6384213v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"2674375","version":"1","preferredName":"Chronic Myeloproliferative Disorder","preferredDefinition":"Chronic myeloproliferative disorders (CMPDs) are clonal hematopoietic stem cell disorders, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, and megakaryocytic) lineages.  The proliferation is associated with relatively normal, effective maturation, resulting in increased numbers of granulocytes, red blood cells, and/or platelets in the peripheral blood.  CMPDs are primarily diseases of adults.  -- 2003","longName":"C4345","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myeloproliferative Neoplasm","conceptCode":"C4345","definition":"A group of myeloid neoplasms that includes the following: chronic myeloid leukemia, BCR-ABL1 positive; polycythemia vera; essential thrombocythemia;  primary myelofibrosis; chronic neutrophilic leukemia; chronic eosinophilic leukemia, not otherwise specified; and myeloproliferative neoplasm, unclassifiable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"383B5884-C0F0-59CB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-21","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-21","modifiedBy":"ONEDATA","dateModified":"2007-08-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6384213","version":"1","preferredName":"Blast Count Assessment","preferredDefinition":"The determination of the number of blast cells present in a blood sample.:The final result of a determination of the value, significance, or extent of.","longName":"C74605:C25367","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Blast Count","conceptCode":"C74605","definition":"The determination of the number of blast cells present in a biospecimen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Assessment","conceptCode":"C25367","definition":"The final result of a determination of the value, significance, or extent of.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"72C7FF1A-291D-344B-E053-F662850A067A","latestVersionIndicator":"Yes","beginDate":"2018-08-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-06","modifiedBy":"ONEDATA","dateModified":"2018-08-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"72C7FF1A-292E-344B-E053-F662850A067A","latestVersionIndicator":"Yes","beginDate":"2018-08-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-06","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeDescription":"11/8/18 TT released.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6384254","version":"1","preferredName":"Less Than Or Equal To Twenty Myeloproliferative Neoplasm Code","preferredDefinition":"A statement about the relative size or order of two objects specifying that an object of interest exceeds another object in quantity or measure or value or status._A natural number greater than nineteen and less than twenty-one and the quantity that it denotes._A condition or state at a particular time.._The final result of a determination of the value, significance, or extent of._A statement about the relative size or order of two objects specifying that an object of interest exceeds another object in quantity or measure or value or status._A natural number greater than nineteen and less than twenty-one and the quantity that it denotes._A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008)_A symbol or combination of symbols which is assigned to the members of a collection._A statement about the relative size or order of two objects specifying that an object of interest is smaller than another object in quantity or measure or value or status._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._The quality of being the same in quantity or measure or value or status._Used as a function word to indicate direction, purpose, or movement._A natural number greater than nineteen and less than twenty-one and the quantity that it denotes._A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008)_A symbol or combination of symbols which is assigned to the members of a collection.","longName":"6384254v1.0","context":"Theradex","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"2","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"CB","valueDescription":"Clinical Benefit","ValueMeaning":{"publicId":"6384034","version":"1","preferredName":"Clinical Benefit","longName":"6384034","preferredDefinition":"An effect of a therapeutic intervention that prolongs life, improves function, and/or improves the way a subject feels.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Benefit","conceptCode":"C142422","definition":"An effect of a therapeutic intervention that prolongs life, improves function, and/or improves the way a subject feels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"72C6BAFD-61E4-3006-E053-F662850A9BF1","latestVersionIndicator":"Yes","beginDate":"2018-08-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-06","modifiedBy":"ONEDATA","dateModified":"2018-08-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"72C7FF1A-299D-344B-E053-F662850A067A","beginDate":"2018-08-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-06","modifiedBy":"ONEDATA","dateModified":"2018-08-06","deletedIndicator":"No"},{"value":"MS","valueDescription":"Bone Marrow Response","ValueMeaning":{"publicId":"6384035","version":"1","preferredName":"Bone Marrow Response","longName":"6384035","preferredDefinition":"The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes.: Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bone Marrow","conceptCode":"C12431","definition":"The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Response","conceptCode":"C25755","definition":"Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"72C6BAFD-620C-3006-E053-F662850A9BF1","latestVersionIndicator":"Yes","beginDate":"2018-08-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-06","modifiedBy":"ONEDATA","dateModified":"2018-08-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"72C7FF1A-29B2-344B-E053-F662850A067A","beginDate":"2018-08-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-06","modifiedBy":"ONEDATA","dateModified":"2018-08-06","deletedIndicator":"No"},{"value":"PM","valueDescription":"Partial Remission","ValueMeaning":{"publicId":"3951935","version":"1","preferredName":"Partial Remission","longName":"3951935","preferredDefinition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Partial Remission","conceptCode":"C18058","definition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB155E17-C5B7-CEC3-E040-BB89AD4342C2","latestVersionIndicator":"Yes","beginDate":"2013-11-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"72C7FF1A-29C8-344B-E053-F662850A067A","beginDate":"2018-08-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-06","modifiedBy":"ONEDATA","dateModified":"2018-08-06","deletedIndicator":"No"},{"value":"CM","valueDescription":"Cytogenetic Complete Response","ValueMeaning":{"publicId":"5508164","version":"1","preferredName":"Cytogenetic Complete Response","longName":"5508164","preferredDefinition":"The disappearance of all signs of cancer, including the absence of a detectable disease-related genetic abnormality, as determined by techniques such as karyotyping or FISH, in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytogenetic Complete Response","conceptCode":"C123578","definition":"The disappearance of all signs of cancer, including the absence of a detectable disease-related genetic abnormality, as determined by techniques such as karyotyping or FISH, in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3E4A5C62-66C7-5C40-E053-F662850A331B","latestVersionIndicator":"Yes","beginDate":"2016-10-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-10-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"72C7FF1A-29DC-344B-E053-F662850A067A","beginDate":"2018-08-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-06","modifiedBy":"ONEDATA","dateModified":"2018-08-06","deletedIndicator":"No"},{"value":"RM","valueDescription":"Complete Remission","ValueMeaning":{"publicId":"3854972","version":"1","preferredName":"Complete Remission","longName":"3854972","preferredDefinition":"The disappearance of all signs of cancer in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3DF4512-86FD-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Manually curated for OHSU 10262","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"72DCC6FF-DA5B-5562-E053-F662850AF5EA","beginDate":"2018-08-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-07","modifiedBy":"ONEDATA","dateModified":"2018-08-07","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6384253","version":"1","preferredName":"Less Than Or Equality To Twenty Myeloproliferative Neoplasm Code","preferredDefinition":"A statement about the relative size or order of two objects specifying that an object of interest is smaller than another object in quantity or measure or value or status.:An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:The quality of being the same in quantity or measure or value or status.:Used as a function word to indicate direction, purpose, or movement.:A natural number greater than nineteen and less than twenty-one and the quantity that it denotes.:A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008):A symbol or combination of symbols which is assigned to the members of a collection.","longName":"6384253v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Less Than","conceptCode":"C61585","definition":"A statement about the relative size or order of two objects specifying that an object of interest is smaller than another object in quantity or measure or value or status.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Equality","conceptCode":"C61582","definition":"The quality of being the same in quantity or measure or value or status.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"To","conceptCode":"C65107","definition":"Used as a function word to indicate direction, purpose, or movement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Twenty","conceptCode":"C105799","definition":"A natural number greater than nineteen and less than twenty-one and the quantity that it denotes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Myeloproliferative Neoplasm","conceptCode":"C4345","definition":"A group of myeloid neoplasms that includes the following: chronic myeloid leukemia, BCR-ABL1 positive; polycythemia vera; essential thrombocythemia;  primary myelofibrosis; chronic neutrophilic leukemia; chronic eosinophilic leukemia, not otherwise specified; and myeloproliferative neoplasm, unclassifiable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"72CC38E6-DC62-33C0-E053-F662850AD5E8","latestVersionIndicator":"Yes","beginDate":"2018-08-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-06","modifiedBy":"ONEDATA","dateModified":"2018-08-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"72CC38E6-DC73-33C0-E053-F662850AD5E8","latestVersionIndicator":"Yes","beginDate":"2018-08-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-06","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeDescription":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"What is the patient's disease","type":"Preferred Question Text","description":"What is the patient's disease response for this assessment per revised MPN criteria in section 11.2 table 2(if blasts less than or equal to 20% at baseline)?","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Assessment per revised MPN criteria if blasts less than or equal to 20 percent at baseline","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"72C9D925-F51A-3753-E053-F662850A82E6","latestVersionIndicator":"Yes","beginDate":"2018-08-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-06","modifiedBy":"SOKKERL","dateModified":"2019-04-30","changeDescription":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}